Glioma is the most common and fatal primary brain tumor. Thus far, therapeutic strategies to efficiently and specifically antagonize glioma are limited and poorly developed. Here we report that glia-enriched miR-135a, a microRNA that is dramatically downregulated in malignant glioma and correlated with the pathological grading, is capable of inducing mitochondria-dependent apoptosis of malignant glioma by regulating various genes including STAT6, SMAD5 and BMPR2, as well as affecting the signaling pathway downstream. Moreover, this lethal effect is selectively towards malignant glioma cells, but not neurons and glial cells, through a novel mechanism. Our findings suggest an important role of miR-135a in glioma etiology and provide a potential candidate for malignant glioma therapy.
Introduction
Glioma is the most common and fatal primary tumor in the central nervous system (CNS). Treatment strategies combining surgery, radiotherapy and chemotherapy are required for glioma, especially that with malignancy. Unfortunately, the prognosis of patients suffering from malignant glioma such as glioblastoma multiforme remains poor with a median survival in the range of 12-15 months (Wen and Kesari, 2008) . Hence, developments of efficient therapies that specially target glioma cells are urgently needed.
Small interfering RNA (siRNA)-based therapeutics holds great promises as nucleic-acid drugs, especially for single-gene diseases, because of its high specificity and low cytotoxicity. However, cancer is a type of multigenic disease. Single-gene-directed siRNA strategies may fall short in cancer therapy. MicroRNAs (miRNAs) are endogenous small non-coding RNAs that act as crucial gene regulators at post-transcriptional level. One miR-NA is capable of targeting a number of genes to regulate biological processes globally. 128 and 137, and so on, have been documented as tumor suppressors capable of inhibiting cell proliferation of glioma by targeting different oncogenes (Godlewski et al., 2008; Silber et al., 2008; Zhang et al., 2009) .
On the basis of the current understanding on the roles of tumor suppressors in glioma, these miRNAs are attractive for serving as nucleic-acid drugs. Nevertheless, an obstacle in their further clinical development is the potential non-specific toxic side effect of miRNAbased therapeutics. However, some of the miRNAs are tissue-specific or tissue-enriched, such as miR-122 in liver (Girard et al., 2008) and miR-124 in brain (LagosQuintana et al., 2002) . So far, such miRNAs have only been studied in corresponding cell types. If ectopic delivery of these miRNAs into other cell types is well tolerated, tissue-specific or -enriched miRNAs could be more promising candidates for therapy.
In this study, we characterized glia-enriched miR135a that is frequently downregulated in malignant glioma and negatively correlates with the pathological grading. This miRNA is capable of inducing mitochondria-dependent apoptosis of malignant glioma both in vitro and in vivo. We identified signal transducer and activator of transcription 6 (STAT6), SMAD family member 5 (SMAD5) and BMPR2 (bone morphogenetic protein receptor, type II) as target genes of miRNA-135a by combining bioinformatics and protein array approaches. Our data revealed that miR-135a could target malignant glioma cells selectively without affecting normal glial cells and neurons. Our findings not only suggest an evidence of pathology and provide a valuable therapeutic candidate for glioma, but also offer a model for studying the functional selectivity of miRNAs.
Results

Glia-enriched miR-135a is downregulated in malignant glioma
We hypothesized that miRNAs, which are abundant in normal brain but aberrant in malignant glioma could be the potential candidates for drug development. Through mining candidates on mimiRNA (Ritchie et al., 2010) , miR2Disease Base (Jiang et al., 2009) and miRNAMap (Hsu et al., 2008) database, miR-135a caught our attention and its property of brain-enriched was confirmed by quantitative real-time PCR (qPCR) (Figure 1a ).
We firstly measured miR-135a expression level in malignant glioma cell lines. Except for U251 cells, other conventional malignant glioma cell lines, including C6, MGR2, T98G and U87 cells, all exhibited dramatically lower level of miR-135a as compared with normal primary cultured glial cells (rat) and glia cell line human embryonic brain (HEB) (human), respectively ( Figure 1b) . Interestingly, rat cortical neurons (CN) and cerebellar granule neurons (CGN) also exhibited a small amount of endogenous miR-135a, indicating this miRNA is enriched in glia cell. By profiling miRNA135a expression in human glioma tissue samples, we found that the level of endogenous miR-135a were negatively correlated with the pathological grading (Figure 1c) , suggesting an etiological role of miR-135a reduction in glioma progression.
MiR-135a selectively induces mitochondria-dependent apoptosis of malignant glioma Considering that C6, T98G and MGR2 cells have the lowest level of miR-135a, we chose these cell lines as our models to examine whether supplementing exogenous miR-135a could be inhibitory to their survivability.
Cell viability was measured before by fluorescein diacetate staining and methyl thiazolyl tetrazolium assay. Malignant cells including three primary cultured cell samples from patients, and normal CNS-derived cells including rat glia, CN, CGN and normal human glia cell line HEB, were transfected with miR-135a mimics. Figure 2a (also see Supplementary Figure S2a) shows that the viability of malignant glioma cells was suppressed by miR-135a compared with miRNA mimics negative control (NC) transfected group. In contrast, except for a slight viability reduction in rat glia, all other normal CNS-derived cells were not affected. This selective lethal effect is not depended on transfection deficiency. All these cells are efficiently transfected (Supplementary Figures S1a) .
To investigate how cells were disrupted, we performed Annexin V/PI flow-cytometry assay to distinguish between apoptosis and necrosis. Figure 2b shows that the rate of early apoptotic C6 cells was increased from 15.63 to 40.34% after miR-135a transfection. Nevertheless, the cell cycle distribution was not dramatically altered (Supplementary Figures S2b) . Through Hoechst 33342 staining, we further confirmed that the apoptosis rates were dramatically elevated after transfected with miR-135a both in malignant glioma cell lines and primary glioma cell cultures, but not in normal CNS-derived cells (Figure 2c ).
Caspases are in charge of apoptotic signaling and caspase-9 is directly activated in mitochondrial pathway (Budihardjo et al., 1999) . We confirmed that caspase-3/ 7, two terminal executioners in apoptosis, were activated by miR-135a in malignant glioma cell lines (Figure 2d ). In addition, we found that caspase-9 activity was also induced by miR-135a (Figure 2e ). Correspondingly, the apoptotic effect on malignant glioma cell lines induced by miR-135a was attenuated by caspase-9 inhibitor Z-LEHD-FMK (Figure 2f ). On the other hand, the activities of these caspases in rat glia cells were only slightly elevated, but those in other normal CNS-derived cells were not affected. These data imply that miR-135a is capable of selectively triggering mitochondria-dependent apoptosis in malignant glioma cells, but ineffective in normal CNS-derived cells.
MiR-135a suppresses tumorigenicity of C6 cells in vitro and in vivo The significant reduction of miR-135a expression and its potent induction of apoptosis in malignant glioma miR-135a selectively induces apoptosis of glioma S Wu et al hinted us to explore its ability to suppress tumorigenicity of malignant glioma cell lines. First, foci formation assays were performed on C6 cells. Figure 3a shows that miR-135a-transfected C6 cells displayed much fewer and smaller foci as compared with NC-transfected group. Three in vivo models were then employed to investigate the suppression of tumorigenicity in murine. The first model is pretreated xenograft model. Viable NC-or miR-135a-transfected C6 cells were injected subcutaneously (s.c.) into both flanks of the nude mice, respectively. Figure 3b shows that tumors of NCpretreated group grew much faster than miR-135a-pretreated group in the first 2 weeks. At day 15, the average volume of tumors in NC-pretreated group was B3-fold (0.68 ± 0.16 cm 3 versus 0.21 ± 0.05 cm 3 ) larger than miR-135a-pretreated group (Figure 3b and Supplementary Figure S3a) .
To study the long-term effect of miR-135a inhibition on tumor suppression in vivo, we designed an in situ homologous glioma model. Rat-glioma-derived C6 cells were pretreated as described above and injected into rats' cerebral cortex. In order to maintain the effect of the miRNA mimics, 10 days later we performed a single injection of NC-and miR-135a-agomir (NC-chol and miR-135a-chol) into the same point of tumor inoculation. Interestingly, rats of NC-group all failed to survive. Only one rat was dead in miR-135a-group during the next 2 months ( Figure 3c ).
As it is very difficult to monitor the dynamic effect of miR-135a on tumor growth in the second model, we performed intratumoral injection on nude mice as the third model to assess feasibility of using miR-135a therapeutics for malignant glioma treatment. To this end, non-treated C6 cells were injected s.c. into the right flank of the nude mice. When tumors of both groups became visible (B20 mm 3 ) on the 8th day, NC-chol and miR-135a-chol were injected into the tumors, respectively, at indicated time points. Even though intratumoral injections could not achieve uniform spread of miRNA in tumors, miR-135a-chol remarkably suppressed the growth of xenografts ( Figure 3d and Supplementary Figure S3b ). TUNEL assays on slices of xenografts further confirmed that the suppressing effect resulted from apoptosis (Supplementary Figure 3c ).
MiR-135a targets genes associated with mitochondrial apoptotic pathway in malignant glioma
To investigate the mechanism through which miR-135a induced apoptosis of malignant glioma, we searched putative target genes by using TargetScan (Lewis et al., 2005) and DIANA-microT (Maragkakis et al., 2009) algorithms, and suggested that STAT6 and SMAD5 may associate with apoptosis (Sun et al., 2005; Zhang et al., 2008) . We firstly transfected miR-135a and examined the protein levels of STAT6 and SMAD5 by western blotting. Figure 4a shows that miR-135a was capable of downregulating these targets on C6 and T98G cells in a doserelated fashion. We also use immunohistochemistry (IHC) to assess this effect in vivo. Figure 4b shows that both STAT6 and SMAD5 were downregulated in the tissue samples of miR-135a-chol injection group, which were collected from our third animal model. Relative activity of caspase-3/7 and 9 was measured after miR-135a transfection at 36 h pt. (n ¼ 3) (f) 10 mM of caspase-9 inhibitor Z-LEHD-FMK was added after miR-135a transfection and apoptotic rates were counted as above. Dimethyl sulfoxide was served as a vehicle control. (n ¼ 3) (pt, post-transfection; *Po0.05; **Po0.01; ***Po0.001) (pt, post-transfection; *Po0.05; **Po0.01; ***Po0.001).
miR-135a selectively induces apoptosis of glioma S Wu et al
It is well known that miRNAs are a group of multitargeting regulatory genes. Moreover, miRNA-mediated gene regulation is exerted both at translational repression and mRNA degradation level (Nilsen, 2007) . Using traditional gene chips to profile mRNAs and identify target genes of an miRNA may miss some important information. Therefore, we performed protein arrays to identify more potential target genes. Beginning with TargetScan and DIANA-microT prediction, 228 hits with superior score were collected and then inputted into EBIMed (Rebholz-Schuhmann et al., 2007) for literature mining. Those genes associated with malignant phenotypes were documented (Supplementary  Table S1 ). Subsequently, protein arrays for human cells were set up to detect the changes of protein level in T98G cells after transfection. After filtering out negative values and false positive values, we obtained five potential targets of miR-135a (Figure 4c ), which were as follows: APC, BMPR2, FRK, TRPC1 (transient receptor potential cation channel, subfamily C, member 1) and TXNIP (thioredoxin interacting protein). Although the correlations among these genes and glioma phenotypes have not yet been revealed, BMPR2 and TRPC1 draw our attention for further investigation.
BMPR2 supports survival by stabilizing XIAP ), a potent inhibitor of apoptosis through caspase-3/7 inhibition (Yang and Li, 2000) . Ca 2 þ channel TRPC1, whose disruption can reduce glioma proliferation (Bomben and Sontheimer, 2010) , seems to be required by glioma. To validate the direct interactions between miR-135a and these potential targets, reporter gene constructs with the putative binding sites of STAT6, SMAD5, BMPR2 and TRPC1 (Supplementary Figure S4 ) cloned into 3 0 -UTRs were created and dual-luciferase reporter assays were carried out in C6 cells. Figure 4d shows those luminescence values of wildtype UTRs with miR-135a mimics were significantly lower than the other groups in STAT6, SMAD5 and BMPR2 panels. Unfortunately, TRPC1 did not show the same pattern, indicating this gene was not the direct target of miR-135a in our model. Furthermore, silencing STAT6, SMAD5 and BMPR2 alone is capable of mimicking the effect of miR-135a that elevated the activity of caspase-3/7 significantly, and combining knocked-down of all these genes contributed to greater level of caspase-3/7 activity (Figure 4e ). STAT6 has been demonstrated that positively govern the transcription of Bcl-xl (Masuda et al., 2001; Wurster et al., 2002) , which is an anti-apoptotic member of the BCL-2 family. Our data indicated that, by either silencing STAT6 or miR-135a transfection in C6 cells, miR-135a selectively induces apoptosis of glioma S Wu et al the mRNA level of Bcl-xl was significantly downregulated (Figure 4f ). SMAD5 is considered to involve in the transcription of Survivin in prostate cancer (Yang et al., 2006; Lim et al., 2010) , which is a small inhibitor of apoptosis by heightening survival signaling around mitochondria (Altieri, 2008) . By transfecting miR-135a or silencing SMAD5, Survivin was downregulated significantly (Figure 4f ). Interestingly, with simultaneously silencing STAT6 and SMAD5, the potent proapoptotic factor Bax (Kim et al., 2009 ) was remarkably upregulated just as miR-135a transfection (Figure 4f ). Taken together, these results suggest that miR-135a induces apoptosis of malignant glioma cells by targeting various genes including STAT6, SMAD5 and BMPR2 synergistically, thus affecting the survival pathway of mitochondria.
Cell-type-dependent functional heterogeneity of miR-135a determines its selective lethal effect on malignant glioma MiRNAs function as regulators of their target genes. Surprisingly, our study revealed that miR-135a did not potently regulate some target genes in HEB cell. We performed dual-luciferase reporter assays in HEB cells. Figure 5a shows that miR-135a did not directly interact with the putative binding sites of SMAD5 and BMPR2. Even though miR-135a still directly bound to the predicted site of STAT6, the average level of luciferase activity inhibition was remarkably attenuated in comparison with the same assay on C6 cells (29% inhibition in HEB versus 75% in C6).
We further confirmed that miR-135a also did not remarkably suppress the protein levels of STAT6 and SMAD5 in normal CNS-derived cells (Figure 5b ). We and TRPC1. Renilla luciferase activity was normalized with firefly luciferase activity and relative luciferase activity was calculated. WT, wild-type UTR; Mut, mutant-type UTR. *, WT þ miR-135a versus WT þ NC; #, Mut þ miR-135a versus WT þ miR-135a. (n ¼ 3) (e) Apoptosis were documented by measuring the activity of endogenous caspase-3/7 after silencing the target genes. NC Â 3 indicates 3-fold dose of negative siRNA control and served as the control of combining knockdown. No statistical significance between the data of NC and NC Â 3 group. (n ¼ 3) (f) The mRNA level of mitochondria-related apoptotic factors related to STAT6 and SMAD5 were measured by qRT-PCR after miR-135a transfection or target genes silencing in C6 cells. (n ¼ 3) (*Po0.05; **, ## Po0.01; ***Po0.001).
miR-135a selectively induces apoptosis of glioma S Wu et al also scanned the sequence around the binding site of miR-135a in STAT6. No difference was found between T98G and HEB cells compared with the information from GenBank (Supplementary Figure S5a) . In protein arrays, four out of five potential targets also escaped from miR-135a regulation in HEB cells at the sensitivity of our detection assay. Although we demonstrated that TRPC1 was not the direct target of miR-135a, the indirect suppressing effect on TRPC1 was also extinguished ( Figure 5c ). Another target BMPR2 was undetectable by protein array in HEB cells. Interestingly, T98G cells expressed BMPR2 abundantly (Figure 5d ). In sum, the selective effect of miR-135a could possibly accomplish through two pathways: deregulation of some target genes in normal CNSderived cells, and targeting some over-expressed oncogenes in malignant glioma cells.
Discussion
MiRNAs have been described to be associated with cancer initiation and progression. Independent research groups have reported significant miRNA alteration in glioma by profiling (Gaur et al., 2007; Malzkorn et al., 2010) . Among these aberrant miRNAs in malignant glioma, miR-124 and miR-128 are better characterized. Together with miR-137, miR-124 inhibits the proliferation of glioblastoma cells by targeting cyclin-dependent kinase 6 (Silber et al., 2008; Li et al., 2009) . Strong evidences support that miR-128 act as a tumorigenetic marker of glioma. This miRNA inhibits proliferation and self-renewal of glioma by targeting transcription factor E2F3a and oncogene Bmi1 (Godlewski et al., 2008; Zhang et al., 2009) . In this study, we confirmed that miR-135a is a glia-enriched miRNA, suggesting its key role in functional maintenance of CNS. This miRNA is frequently downregulated in malignant glioma cells. Furthermore, the level of endogenous miR-135a is negatively correlated with the glioma pathological grading, indicating an association with the pathogenesis of glioma. Therefore, it is also possible to be developed into a biomarker for diagnosis. We showed that miR-135a is capable of inducing mitochondria-dependent apoptosis of malignant glioma by targeting various genes. We identified STAT6, SMAD5 and BMPR2 as direct targets of miR-135a. Our finding on SMAD5 is consistent with previous report . Among these, STAT6 and SMAD5 were directly linked to mitochondrial pathways of apoptosis by participating in the transcription of Bcl-xl and Survivin, and the modulation of Bax. We found significant elevation of the activity of caspase-3/7 by silencing one single target gene alone, and combining silencing three target genes contributes to greater caspase-3/7 activity induction. This result suggests that synergic multi-targeting is essential for miRNAs.
Our findings on therapeutic delivery of miR-135a in vivo provide a key to therapeutics for malignant glioma. In homologous in situ glioma model, miR-135a significantly prolonged the overall survival. For brain tumor, delivery strategies effectively penetrating bloodbrain barrier into parenchyma are urgently demanded. Nucleic-acid drugs, such as miRNAs, can be directly synthesized and modified to be more lipophilic that improves penetration. Such modification may include cholesterylation and coupling with nanoparticles (Beduneau et al., 2007) . Our delivery of miR-135a agomirs, which are cholesterylated miRNA mimics, successfully shrunk tumor sizes in intratumoral injection model. However, we observed that the effect of intratumoral injection was more modest than pretreated models. This might be due to distinct tumor growth environments among different models, and drug-diffusing restriction by direct injection. Nevertheless, combined with the finding of selectivity, miR-135a suggests an enormous potential for further drug development.
We demonstrated that miR-135a is selectively lethal to malignant glioma cells, but neutral in CNS-derived cells in vitro. Although miR-135a somewhat inhibited the viability of rat glia cells, no significant lethal effect were observed in rat CN, CGN and human glia cell models. This finding is similar to the report about systemic administration of miR-26a. Janaiah Kota et al. miR-135a selectively induces apoptosis of glioma S Wu et al (Kota et al., 2009 ) have characterized that miR-26a is capable of reducing proliferation and inducing tumorspecific apoptosis in hepatoma carcinoma cells. They proposed that as miR-26a is highly expressed in many normal tissues, but specifically downregulated in Mycinduced liver tumor, systemic administration of this therapeutic miRNA is well tolerated. In consideration that HEB cells have high level of endogenous miR-135a, the binding sites within some key target genes might have been saturated so that exogenous delivery of miR135a could not dramatically alter the expression level of these genes, which is consistent with our dual-luciferase reporter assays in HEB cell.
However, the hypothesis about tolerance only provides a partial explanation in our models, for CN and CGN did not highly express miR-135a. So far, it is known that miRNA are modulated in biogenesis, activity and degradation level (Siomi and Siomi, 2010) . In this circumstance of ectopic delivery, we considered that regulation of activity may be the mechanism. Victor Ambros and co-workers led the way in finding that TRIM-NHL family protein NHL-2 positively regulates miRNA activity in Caenorhabditis elegans (Hammell et al., 2009 ). Although we found that the selective lethal effect of miR-135a may not associate with TRIM32 (homologue with NHL-2 in our models, see Supplementary Figure S5b) , virtually, this result is correlated with the previous finding that not every miRNA's activity is regulated by TRIM32 (Schwamborn et al., 2009).
Moreover, miR-135a functions diversely in different cell types. In colorectal cancer, miR-135a seems to be an onco-like miRNA by targeting APC (Nagel et al., 2008) . But in classic Hodgkin's lymphoma, this miRNA can induce apoptosis of L-428 cells by targeting JAK2 (Navarro et al., 2009) . From another point of view, different cell type, such as normal CNS-derived cells versus glioma cells, may rely on distinct pathways of apoptosis, thus the function of miRNAs could be varied. We illustrated that miR-135a lost its regulating capacity towards some target genes in normal cell type (STAT6 and SMAD5), and targeted a (but should be more) gene that highly expressed in malignant glioma cell type (BMPR2). In this context, the characteristic of cell-type-dependent functional heterogeneity of miRNAs may provide a possible explanation. Although the underlying mechanism is not clear by now, we believe that this attractive scientific problem can be solved by modern high throughput technologies such as RNAi screening.
In summary, we report that glia-enriched miR-135a is frequently downregulated in malignant glioma. This miRNA is capable of selectively inducing mitochondriadependent apoptosis of malignant glioma cells, but not normal CNS-derived cells. As a result, miR-135a not only offers an evidence of pathology and diagnostics for glioma, but also casts a new light on malignant glioma therapy. Furthermore, miR-135a and its selective lethal effect provide a suitable model for studying the biology of cell-type-dependent functional heterogeneity of miRNA.
Materials and methods
Cells and tissues
Malignant glioma cell lines C6 (rat), T98G, MGR2, U87 and U251 (human) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human normal glial cell line HEB, originally established by Kedar N. Prasad et al. (Kumar et al., 2001; Nahreini et al., 2003) was purchased from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. Rat primary cortical glial cells and neurons were isolated from Sprague-Dawley rat, respectively.
All cell lines were grown in regular medium (Dulbecco 0 s Modified Eagle Medium, with 10% fetal bovine serum and 1% antibiotics). Rat primary CN were maintained in Neurobasal medium with 5% fetal bovine serum, 2% B-27, 1% L-glutamine and 1% antibiotics; CGN were in BME with 10% fetal bovine serum, 25 mmol KCl and 1% antibiotics; glia were in Dulbecco 0 s Modified Eagle Medium with 10% fetal bovine serum and 1% antibiotics. Except for glia, mediums were changed to serum-free when assays were carried out.
Human glioma samples from surgery were obtained from the neurosurgery department of Tumor Hospital and the 3rd Affiliated Hospital of Sun Yat-sen University. Formalin-fixed paraffin-embedded human glioma tissue samples were obtained from the pathology department of the 1st and 3rd Affiliated Hospital of Sun Yat-sen University.
RNA isolation, reverse transcription and quantitative real-time PCR Total RNAs were isolated by TRIzol reagent (Invitrogen, Grand Island, NY, USA). For formalin-fixed paraffinembedded samples, the blocks were sliced into 30 mm thick pieces. After deparaffinization with xylene and wash by ethanol, tissues were digested with Proteinase K (BBI Enzymes, Blaenavon, UK) followed with TRIzol extraction.
Reverse transcription was performed using SuperScript III reverse transcriptase (Invitrogen). qPCR was performed with Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and detected with the LightCycler 480 instrument (Roche, Basel, Switzerland). Comparative CT method (2 ÀDDCT ) was adopted to evaluate the relative quantitation. The level of U6 and b-actin was used to normalize miRNA and mRNA level, respectively. Primers of stem-loop method for miR-135a detection are: Stem-loop reverse transcription primer CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAG TCACATAG; Forward PCR primer ACACTCCAGCTCAG TATGGCTTTTTATTCCTATGT; Reverse PCR primer: CTCAACTGGTGTCGTGGAGTCGGCAATTCAG.
Cloning and transfection
For dual-luciferase reporter experiment, DNA oligos of 3 0 -UTR segment of target genes predicted to interact with miR135a including Xho I and Not I cohesive end were synthesized (Sangon Biotech, Shanghai, China), annealed and constructed into psiCHECK-2 vector (Promega, Madison, WI, USA). The predicted binding sites and mutated regions were shown in Supplementary Figure S4 . C6 and HEB cells were used as the host. Luciferase activity was measured by Dual-Luciferase Reporter Assay System (Promega). Renilla luciferase activity was normalized with firefly luciferase activity. Double strand miRNA mimics and siRNAs were designed and synthesized by RiboBio (Guangzhou, China). 100 nM of the mimics and 50 nM of siRNAs were transfected by Lipofectamine RNAiMAX (Invitrogen), according to the manual. Double strand scramble RNA was used as the NC. The transfection and miR-135a selectively induces apoptosis of glioma S Wu et al silencing efficiency were monitored by Cy3-labeled RNA mimics and qPCR (Supplementary Figure S1) .
Cell viability and apoptosis assay
Cell viability was determined by methyl thiazolyl tetrazolium assay. Fluorescein diacetate was used as an indicator of living cells. Apoptosis was evaluated by the flow cytometry, apoptotic morphology, Caspases' activity and TUNEL staining. For flow-cytometry analysis, cells were collected and stained with Annexin V/Propidium Iodide using TACS Annexin V Kits (Trevigen, Gaithersburg, MD, USA) and analyzed by a flow cytometer (Beckman Coulter, Brea, CA, USA). Apoptotic morphology was observed by Hoechst 33342 (Sigma-Aldrich, St Louis, MO, USA) staining. Cells with condensed and fragmented nuclei were considered as the apoptotic cells. Caspases' activity was determined by CaspaseGlo 3/7 and 9 Assay Systems (Promega). TUNEL assay was performed with In situ Cell Death Detection Kit, TMR red (Roche). Caspase-9 inhibitor Z-LEHD-FMK was from SigmaAldrich and dissolved in dimethyl sulfoxide.
Tumorigenicity assay
Tumorigenicity was evaluated by foci-formation assay and in vivo animal models. For foci-formation assay, 200 viable cells pretreated with miRNA mimics for 24 h were placed in 6-well plated in triplicate and maintained in complete medium for 10 days. Foci were fixed with 4% polyoxymethylene and stained with 0.1% crystal violet. ) with miRNA mimics or NC mimics were injected into the cerebral cortex of 200B250 g rats, according to the atlas of Paxinos and Watson. MiRNA agomirs, whose terminal nucleotides at both ends were modified by an O-methyl moiety at the 2 0 -ribose position and the 5 0 end was modified with cholesteryl functionality, were synthesized and diluted in phosphate-buffered saline. Ten days after tumor cell inoculation, single injection of NC or miR-135a agomirs (NCchol and miR-135a-chol, 1 nmol/rat) were injected into the same point of inoculation. Finally, the survival curve was documented until the last rat in either group was dead. For intratumoral injection model, non-treated C6 cells were injected s.c. into the right flanks of nude mice. After one week, NC-chol and miR-135a-chol were injected into the tumor directly 3B4 times a week (1 nmol/mouse). Tumor volume was monitored as above. At the end of the experiment, mice were killed and tumor samples were embedded in paraffin and sliced for TUNEL and IHC assay.
Western blot and IHC Cell lysates were prepared and separated by 10% SDSpolyacrylamide gel electrophoresis. After electroblotted onto a polyvinylidene fluoride membrane (Roche), target proteins were detected with corresponding antibodies (Supplementary  Table S2 ) and Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA). IHC was performed on 2 mm-thick formalin-fixed paraffin-embedded slices. After dewaxing, permeabilizing and blocking, primary and secondary antibodies were incubated sequentially for detection.
Protein array
Label-based antibody array was purchased from RayBiotech (Norcross, GA, USA). Experiment procedures were carried out following the user manual. Briefly, antibodies for target proteins were coated to nitrocellulose membrane and protein samples were labeled with biotin. After incubating the label sample onto the membrane, label streptavidin was used for detection.
Statistical analysis
All experiments were carried out for three times independently. Data are mean±s.d. (n ¼ 3) except special indication. Spearman's rank correlation test was used for association analysis between endogenous miR-135a level data and pathological grading. Kaplan-Meier survival analysis was performed for in situ homologous glioma model. Other data were analyzed by analysis of variance. Differences were considered to be statistically significant at Po0.05 (*Po0.05; **Po0.01; ***Po0.001).
